Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential

SBEV announced a licensing agreement with Argent BioPharma for CannEpil®, its proprietary cannabinoid-based therapeutic being developed for drug-resistant epilepsy (DRE). The deal is a positive commercial/partnership signal for the program, though the news provides no financial terms or timeline impact.

Analysis

SBEV announced a licensing agreement with Argent BioPharma for CannEpil®, its proprietary cannabinoid-based therapeutic being developed for drug-resistant epilepsy (DRE). The deal is a positive commercial/partnership signal for the program, though the news provides no financial terms or timeline impact.